Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

6.910 +0.070 (+1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Analyst Ratings for Cormedix
Analysts have provided the following ratings for Cormedix (NASDAQ:CRMD) within the last quarter: 
Via Benzinga
As CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
Tuesday, CorMedix Inc (NASDAQ: CRMD) resubmitted New Drug Application for DefenCath to the FDA, and the submission has been acknowledged as  
Via Benzinga
What 5 Analyst Ratings Have To Say About Cormedix
Via Benzinga
CorMedix (CRMD) Q1 2023 Earnings Call Transcript
CRMD earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Recap: Cormedix Q1 Earnings
Via Benzinga
Preview: Cormedix's Earnings
Via Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
The late-stage biopharma Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is approaching the conclusion of the phase 3 trial for its drug, Mino-Lok. 
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
Expert Ratings for Cormedix
Via Benzinga
Cormedix's Return On Capital Employed Overview
Via Benzinga
A Preview Of Cormedix's Earnings
Via Benzinga
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers. 
Via InvestorPlace
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
Cormedix's Return On Capital Employed Insights
Via Benzinga
CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript
CRMD earnings call for the period ending September 30, 2022. 
Via The Motley Fool
CorMedix Inc. (NASDAQ:CRMD) Shareholder Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/04/2022 -- Certain directors of CorMedix Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Recap: Cormedix Q2 Earnings
  Cormedix (NASDAQ:CRMD) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CorMedix Inc. (NASDAQ:CRMD) Shareholder Notice: Update in Lawsuit Announced
San Diego, CA -- (SBWIRE) -- 09/21/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of CorMedix Inc. (NASDAQ:CRMD). 
Via SBWire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today
  Cormedix (NASDAQ:CRMD) has outperformed the market over the past 10 years by 2.86% on an annualized basis producing an average annual return of 14.54%. Currently, Cormedix has a market capitalization... 
Via Benzinga
Dow Drops Over 100 Points; Verona Pharma Shares Jump
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday. 
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday. 
Via Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.